These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 27036115)

  • 1. Hepatitis C testing in substance use disorder treatment: the role of program managers in adoption of testing services.
    Frimpong JA; D'Aunno T
    Subst Abuse Treat Prev Policy; 2016 Apr; 11():13. PubMed ID: 27036115
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Provision of and Barriers to Integrating Reproductive and Sexual Health Services for Reproductive-age Women in Opioid Treatment Programs.
    Klaman SL; Lorvick J; Jones HE
    J Addict Med; 2019; 13(6):422-429. PubMed ID: 31689259
    [TBL] [Abstract][Full Text] [Related]  

  • 3. On-site bundled rapid HIV/HCV testing in substance use disorder treatment programs: study protocol for a hybrid design randomized controlled trial.
    Frimpong JA; D'Aunno T; Perlman DC; Strauss SM; Mallow A; Hernandez D; Schackman BR; Feaster DJ; Metsch LR
    Trials; 2016 Mar; 17(1):117. PubMed ID: 26936623
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A study protocol for Project I-Test: a cluster randomized controlled trial of a practice coaching intervention to increase HIV testing in substance use treatment programs.
    Frimpong JA; Parish CL; Feaster DJ; Gooden LK; Nelson MC; Matheson T; Siegel K; Haynes L; Linas BP; Assoumou SA; Tross S; Kyle T; Liguori TK; Toussaint O; Annane D; Metsch LR
    Trials; 2023 Sep; 24(1):609. PubMed ID: 37749635
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Spillover effects of HIV testing policies: changes in HIV testing guidelines and HCV testing practices in drug treatment programs in the United States.
    Frimpong JA; D'Aunno T; Helleringer S; Metsch LR
    BMC Public Health; 2016 Jul; 16():666. PubMed ID: 27473519
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Low Rates of Adoption and Implementation of Rapid HIV Testing in Substance Use Disorder Treatment Programs.
    Frimpong JA; D'Aunno T; Helleringer S; Metsch LR
    J Subst Abuse Treat; 2016 Apr; 63():46-53. PubMed ID: 26810130
    [TBL] [Abstract][Full Text] [Related]  

  • 7. National trends in testing for hepatitis C virus in licensed opioid treatment programs: Differences by facility ownership and state medicaid expansion status.
    Pro G; Tompkins DA; Azari S; Zaller N
    Drug Alcohol Depend; 2021 Nov; 228():109092. PubMed ID: 34571287
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Care Integration for Hepatitis C Virus Treatment Through Facilitated Telemedicine Within Opioid Treatment Programs: Qualitative Study.
    Dickerson SS; George SJ; Ventuneac A; Dharia A; Talal AH
    J Med Internet Res; 2024 Jun; 26():e53049. PubMed ID: 38865703
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Outpatient drug treatment program directors' hepatitis C-related beliefs and their relationship to the provision of HCV services.
    Astone JM; Strauss SM; Hagan H; Des Jarlais DC
    Am J Drug Alcohol Abuse; 2004 Nov; 30(4):783-97. PubMed ID: 15624549
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Determinants of the availability of hepatitis C testing services in opioid treatment programs: results from a national study.
    Frimpong JA; D'Aunno T; Jiang L
    Am J Public Health; 2014 Jun; 104(6):e75-82. PubMed ID: 24825236
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Missed opportunities for hepatitis C testing in opioid treatment programs.
    Frimpong JA
    Am J Public Health; 2013 Jun; 103(6):1028-30. PubMed ID: 23597374
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Provision of onsite HIV Services in Substance Use Disorder Treatment Programs: A Longitudinal Analysis.
    Aletraris L; Roman PM
    J Subst Abuse Treat; 2015 Oct; 57():1-8. PubMed ID: 25934459
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hepatitis B virus and hepatitis C virus services offered by substance abuse treatment programs in the United States.
    Bini EJ; Kritz S; Brown LS; Robinson J; Calsyn D; Alderson D; Tracy K; McAuliffe P; Smith C; Rotrosen J
    J Subst Abuse Treat; 2012 Jun; 42(4):438-45. PubMed ID: 22035702
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Staff perspectives on facilitating the implementation of hepatitis C services at drug treatment programs.
    Munoz-Plaza CE; Strauss SM; Astone-Twerwll JM; Des Jarlais DC; Hagan H
    J Psychoactive Drugs; 2006 Sep; 38(3):233-41. PubMed ID: 17165366
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gaps in the drug-free and methadone treatment program response to Hepatitis C.
    Strauss SM; Astone J; Vassilev ZP; Des Jarlais DC; Hagan H
    J Subst Abuse Treat; 2003 Jun; 24(4):291-7. PubMed ID: 12867202
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A study protocol for Project I-Test: a cluster randomized controlled trial of a practice coaching intervention to increase HIV testing in substance use treatment programs.
    Frimpong JA; Parish C; Feaster DJ; Gooden LK; Matheson T; Haynes L; Linas BP; Assoumou SA; Tross S; Kyle T; Nelson CM; Liguori TK; Toussaint O; Siegel K; Annane D; Metsch LR
    Res Sq; 2023 Jun; ():. PubMed ID: 37461594
    [No Abstract]   [Full Text] [Related]  

  • 17. Viral Hepatitis and Human Immunodeficiency Virus Testing and Linkage to Care for Individuals Enrolled in an Opioid Treatment Program.
    Rowan SE; Kamis KF; Beum R; Bryan K; Gawenus L; Colon Sanchez D; Hurley H
    J Infect Dis; 2020 Sep; 222(Suppl 5):S384-S391. PubMed ID: 32877565
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Improving HIV and HCV Testing in Substance Use Disorder Programs (SUDs) That Provide Medications for Opiate Use Disorder (MOUD): Role of Addressing Barriers and Implementing Universal and Site-Specific Approaches.
    Brooks R; Wegener M; Freeman B; Fowles C; Madden LM; Tetrault JM; Nichols L; Altice FL; Villanueva M
    Health Promot Pract; 2023 Sep; 24(5):1018-1028. PubMed ID: 37439759
    [No Abstract]   [Full Text] [Related]  

  • 19. Evaluation of two community-controlled peer support services for assessment and treatment of hepatitis C virus infection in opioid substitution treatment clinics: The ETHOS study, Australia.
    Treloar C; Rance J; Bath N; Everingham H; Micallef M; Day C; Hazelwood S; Grebely J; Dore GJ
    Int J Drug Policy; 2015 Oct; 26(10):992-8. PubMed ID: 25697089
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Addressing Barriers to On-site HIV and HCV Testing Services in Methadone Maintenance Treatment Programs in the United States: Findings From a National Multisite Qualitative Study.
    Behrends CN; Kapadia SN; Schackman BR; Frimpong JA
    J Public Health Manag Pract; 2021 Jul-Aug 01; 27(4):393-402. PubMed ID: 33346582
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.